Editor's note

This article was originally published on 1 October 2013 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The GPEI Endgame Strategic Plan

The Global Polio Eradication Initiative (GPEI) published its Polio Eradication and Endgame Strategic Plan 2013-2018, which among other objectives requires the 97 countries currently using OPV schedules to introduce at least one dose of inactivated polio vaccine (IPV) into their national immunisation programmes by 2015. The driver is the need to re-establish immunity to Type 2 poliovirus ahead of the planned switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) - which removes the Type 2 component, eliminating vaccine-derived poliovirus cases but also removing protection against the wild Type 2 strain.

Countries Adding IPV
97

Number of OPV-using countries required to introduce at least one IPV dose by 2015 under the GPEI Endgame plan

Cost is the central challenge

IPV manufacturing costs are estimated to be 4-15 times those of OPV and "will never" reach OPV price parity. Meeting the GPEI targets realistically requires IPV to be available at no less than approximately $1 per dose - a price the market will struggle to reach quickly. The Serum Institute of India, which acquired Bilthoven Biologicals in July 2012, fired the opening shot by agreeing to supply IPV at approximately $1.70 per dose, with possible further reductions.

Sabin-IPV: a new competitive dynamic

In 2012, two Sabin-IPV (inactivated poliovirus vaccine based on attenuated Sabin seed strains) were approved in Japan - an important proof-of-concept milestone. Sabin-IPV is safer to manufacture in terms of biosafety containment requirements, potentially enabling production in more countries. This dynamic suggests that the market is not "sewn up" by established Salk-IPV producers - Sanofi Pasteur, GSK, and the Statens Serum Institute.

"The Serum Institute of India has fired the first shot in a potential price war with Western IPV producers - and the global demand surge from the GPEI plan will test supply chains like never before."